Antibody production: comparing an antibody production service, a custom polyclonal antibody project and the antibody production companies behind them, stage by stage

The stages, and where they go wrong

1. Immunogen design decides the outcome. Whether you immunise with a peptide, a recombinant domain or the whole protein determines what the resulting antibodies recognise, and a peptide-raised antibody frequently fails against the folded protein. Choose the immunogen from the application rather than from convenience or cost.
2. Host species and format. The host affects affinity, the epitope repertoire and downstream compatibility with your detection reagents and your species of study. Rabbit, mouse, goat and the camelid single-domain formats each suit different applications, and the choice constrains what you can multiplex with later.
3. Screening is the whole project. Ask what the screen actually is and how closely it resembles your application. A binder selected on a plate against the immunogen may not work in the assay you need, so pay for a screen in the relevant format even where it costs more, because it is much cheaper than a failed reagent.
4. Polyclonal or monoclonal. Polyclonal serum is fast and cheap and is finite: when the animal is gone, the reagent is gone. A monoclonal or a recombinant monoclonal is renewable and consistent and costs more up front. For anything that must be reproducible for years, the renewable route is the cheaper one.
5. Ownership and renewability. Settle who owns the hybridoma, the sequence and the cell line, and whether you can have the variable region sequence. A sequenced antibody can be made again anywhere; a hybridoma in somebody else's freezer is a dependency with a lifetime.

Validation the provider will not do for you

A provider validates that an antibody binds what it was screened against. Whether it works in your tissue, your fixation, your buffer and your assay is your validation, and it is the step most often skipped. Budget for it at the start rather than discovering the gap at the end.

Where reproducibility matters, keep a reference lot and test every new lot against it. Lot variation is the standard failure mode of polyclonal reagents and is not always visible on a certificate.

Comparing quotes

Providers bundle differently: immunogen preparation, animal numbers, bleed schedule, screening depth, purification and the analytics may be inside or outside the headline. Normalise them against your own written scope, particularly the number of clones screened and the format screened in.

Ask what happens if no clone meets the specification. A provider with a clear answer has thought about it; one without is quoting a best case.

Common questions

Polyclonal or monoclonal antibody production?

Polyclonal is faster and cheaper and is a finite resource tied to one animal. Monoclonal, and especially recombinant monoclonal, is renewable and consistent and costs more up front. Long-running work is cheaper on the renewable route.

How long does antibody production take?

It is driven by the immunisation schedule and the depth of screening rather than by the provider. Polyclonal projects are substantially shorter than monoclonal ones, and recombinant routes add sequencing and expression time at the end.

What should I own at the end?

Ideally the sequence of the variable regions, which makes the antibody reproducible anywhere. Failing that, the hybridoma or cell line and the right to have it made. Serum alone is a reagent with an expiry.

Will the provider validate the antibody for my assay?

Only if you pay for a screen in that format. The standard screen tests binding to the immunogen, which does not predict performance in tissue, in a fixed sample or in a complex lysate.

Browse by service class

• Compare Gene synthesis on advertised prices